T
Takeshi Makabe
Researcher at Keio University
Publications - 15
Citations - 121
Takeshi Makabe is an academic researcher from Keio University. The author has contributed to research in topics: Endometrial cancer & Gene. The author has an hindex of 4, co-authored 15 publications receiving 79 citations.
Papers
More filters
Journal ArticleDOI
Genome-wide DNA methylation profile of early-onset endometrial cancer: its correlation with genetic aberrations and comparison with late-onset endometrial cancer.
Takeshi Makabe,Eri Arai,Takuro Hirano,Nanako Ito,Yukihiro Fukamachi,Yoriko Takahashi,Akira Hirasawa,Wataru Yamagami,Nobuyuki Susumu,Nobuyuki Susumu,Daisuke Aoki,Yae Kanai +11 more
TL;DR: Data indicate that genetically and epigenetically different pathways may participate in the development of EEs and LEs, and that DNA methylation profiling may help predict tumors that are less aggressive and amenable to fertility preservation treatment.
Journal ArticleDOI
Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?
Wataru Yamagami,Nobuyuki Susumu,Nobuyuki Susumu,Takeshi Makabe,Kensuke Sakai,Hiroyuki Nomura,Fumio Kataoka,Akira Hirasawa,Kouji Banno,Daisuke Aoki +9 more
TL;DR: Repeated treatment is sufficiently effective for intrauterine recurrence after hormonal therapy for AEH/early G1.
Journal ArticleDOI
A comparison of dye versus fluorescence methods for sentinel lymph node mapping in endometrial cancer
Wataru Yamagami,Nobuyuki Susumu,Fumio Kataoka,Takeshi Makabe,Kensuke Sakai,Tomomi Ninomiya,Michiko Wada,Hiroyuki Nomura,Akira Hirasawa,Kouji Banno,Tadaki Nakahara,Kaori Kameyama,Daisuke Aoki +12 more
TL;DR: Although both dye and fluorescence methods performed well, no method perfectly identified para-aortic SNs and the concomitant use of the RI method is required to detect para- aorticSNs.
Journal ArticleDOI
Efficacy and safety of dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube or peritoneal cancer.
Tomoko Yoshihama,Hiroyuki Nomura,Naomi Iwasa,Fumio Kataoka,Shiho Hashimoto,Yoshiko Nanki,Takuro Hirano,Takeshi Makabe,Kensuke Sakai,Wataru Yamagami,Akira Hirasawa,Daisuke Aoki +11 more
TL;DR: This study showed that ddTC therapy was considerably effective and tolerable as NAC, and the complete surgery rate was high with IDS, and perioperative complications were acceptable.
Journal ArticleDOI
Germline multigene panel testing revealed a BRCA2 pathogenic variant in a patient with suspected Lynch syndrome
Tomoko Yoshihama,Akira Hirasawa,Akira Hirasawa,Kokichi Sugano,Teruhiko Yoshida,Mineko Ushiama,Arisa Ueki,Tomoko Akahane,Yoshiko Nanki,Kensuke Sakai,Takeshi Makabe,Wataru Yamagami,Nobuyuki Susumu,Nobuyuki Susumu,Kaori Kameyama,Kenjiro Kosaki,Daisuke Aoki +16 more
TL;DR: In this case, with conventional genetic risk assessment, the patient was unable to determine whether the patient had a high risk of hereditary breast and ovarian cancer; thus, germline multigene panel testing may provide valuable information to improve disease management strategies for patients in clinical settings.